ARM B: Blocks Therapy Drug — Competitive Intelligence Brief

ARM B: Blocks Therapy Drug (ARM B: Blocks Therapy Drug) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-blocker. Area: Oncology.

phase 3 Beta-blocker Beta-adrenergic receptor Oncology Small molecule

Target snapshot

ARM B: Blocks Therapy Drug (ARM B: Blocks Therapy Drug) — Grupo Argentino de Tratamiento de la Leucemia Aguda. ARM B: Blocks Therapy Drug inhibits beta-adrenergic receptors to reduce sympathetic nervous system activity in acute leukemia treatment.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ARM B: Blocks Therapy Drug TARGET	ARM B: Blocks Therapy Drug	Grupo Argentino de Tratamiento de la Leucemia Aguda	phase 3	Beta-blocker	Beta-adrenergic receptor
ISOPROTERENOL	ISOPROTERENOL		marketed	Beta-adrenergic agonist	beta-adrenergic receptors	1956-01-01
Norepinephrine Bitartrate In 5% Dextrose	NOREPINEPHRINE	Pfizer	marketed	Catecholamine	alpha-adrenergic receptors, beta-adrenergic receptors	1950-01-01
Propranolol+pyridostigmine	Propranolol+pyridostigmine	Seoul National University Hospital	marketed	Beta-blocker + Acetylcholinesterase inhibitor combination	Beta-adrenergic receptors; Acetylcholinesterase
Beta blocker/digoxine/amiodarone	Beta blocker/digoxine/amiodarone	Hospital Clinic of Barcelona	marketed	Combination antiarrhythmic/inotropic therapy	Beta-adrenergic receptors, Na+/K+-ATPase, cardiac ion channels (sodium, potassium, calcium)
latanoprost/timolol fixed combination drops	latanoprost/timolol fixed combination drops	Aristotle University Of Thessaloniki	marketed	Prostaglandin analog / Beta-blocker combination	Prostaglandin F receptor (FP receptor) / Beta-adrenergic receptors (β1 and β2)
amiodarone amiodarone	amiodarone amiodarone	National Heart, Lung, and Blood Institute (NHLBI)	marketed	Class III antiarrhythmic agent	Potassium channels (hERG), sodium channels, beta-adrenergic receptors, calcium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-blocker class)

1. Abbott · 1 drug in this class
2. Centre Hospitalier Universitaire de Nice · 1 drug in this class
3. Grupo Argentino de Tratamiento de la Leucemia Aguda · 1 drug in this class
4. Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
5. Sumitomo Pharma (Suzhou) Co., Ltd. · 1 drug in this class